FDA’s Spring Regulatory Agenda Includes 17 Rx Drug-Related Rules
Executive Summary
FDA’s prescription drug regulations in the works include rules on generic drug labeling, compounding, bioequivalence reports and safety reporting for combination products.
You may also be interested in...
Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t
Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.
Electronic Labeling Study By GAO Yields “No Consensus,” Avoids Cost Issue
In study mandated by FDASIA, GAO says there are advantages and disadvantages to switching to an electronic-only system for distributing drug label information, but offers no conclusions.
Combo Product Firms Want Simpler Adverse Event Reporting Structure
FDA's proposed adverse event reporting requirements for combination products should be rewritten to simplify the way events are reported when multiple manufacturers are involved, firms say